NIA (Natl. Inst. on Aging) SBIR/STTR Funding Deadlines: Small Business Funding for Innovations in Alzheimer's Disease and Aging
The National Institute on Aging (NIA) offers early-stage funding opportunities to small businesses and researchers looking to commercialize innovative treatments or technologies to help people enjoy healthier lives as they age.
- Funding is the fuel that helps drive the commercialization of innovation. This two-part workshop will cover a variety of topics related to seeking and obtaining an investment. Topics will cover dilutive versus non-dilutive funding, types of investors and investment capital, capitalization tables and term sheets. The first part of the workshop will help you understand the various types of investors and help you identify the right investor for your business.
- Join us on Tuesday, January 25, 2022, at 3:00 p.m. ET to engage with experts on Investment Funding I: Finding the Right Investor. This interactive session, part of the Entrepreneur Workshop Series, is co-hosted by the National Institute on Aging (NIA) and the National Heart, Lung, and Blood Institute (NHLBI) Small Business Programs in collaboration with the National Institute of Health Office of Extramural Research Small Business Education and Entrepreneurial Development (SEED) office.
- The NIA Small Business Program is accepting applications for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) funding. Learn more about these open opportunities. The next deadlined are April 5 & September 5. 2022.
Funding Speakers:
Current Funding Opportunities
All applicants should consider submitting through the Omnibus Solicitation, which covers a broad range of NIA research topics and investigator-initiated ideas. For small businesses and research organizations working on solutions for Alzheimer’s disease (AD) and AD-related dementias (ADRD), NIA has targeted solicitations for SBIR and STTR that allow for higher budget limits of up to $500,000 for Phase I and $2.5 million for Phase II. These opportunities are part of NIA’s unprecedented research and development budget to develop AD/ADRD interventions and therapeutics.
The following opportunities are currently open:
2021 NIH SBIR Omnibus Solicitation – Clinical Trial Required
- SBIR (PA-21-260)
- STTR (PA-21-261)
2021 NIH SBIR Omnibus Solicitation – Clinical Trial Not Allowed
- SBIR (PA-21-259)
- STTR (PA-21-262)
Advancing Research on Alzheimer’s Disease (AD) and Alzheimer’s Disease-Related Dementias (ADRD)
- SBIR (PAS-19-316)
- STTR (PAS-19-317)
Commercialization Readiness Pilot (CRP) Program:
- SBIR & STTR PA-20-128 (SB1, Technical Assistance) — Clinical Trial Not Allowed
- SBIR & STTR PA-20-129 (SB1, Technical Assistance, and Late Stage Development) — Clinical Trial Not Allowed
- SBIR & STTR PA-20-130 (SB1, Technical Assistance, and Late Stage Development) — Clinical Trial Required
For a list of NIA SBIR and STTR funding opportunities, deadlines, and budget limits, visit the NIA Small Business Program funding page.
Wharton DC Members: Click below to get the link to register and the URL (from a confirming email) for this program.
